Microcap Ledger GT Biopharma, Inc. $GTBP
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- San Francisco, CA
- Fiscal year end
- December 31
- Shares outstanding
- 45,109,497 [10-Q 2026-08-14]
What the company doesAI summary of filing
GT Biopharma is a clinical-stage biopharmaceutical company developing immune-oncology products based on proprietary Tri-specific Killer Engager (TriKE) and Dual Targeting TriKE technology platforms. The company's therapeutics are designed to activate patients' natural killer cells to target and kill cancer cells expressing specific antigens such as CD33, B7-H3, and CD19, and potentially to treat autoimmune disorders. GT Biopharma does not currently generate revenue and relies on third-party contract manufacturers for production of its product candidates. The company has multiple product candidates in development: GTB-3650 targeting CD33+ acute myeloid leukemia and myelodysplastic syndromes (enrollment began January 2025), GTB-5550 targeting B7-H3+ solid tumors (anticipated enrollment mid-2026), and GTB-7550 for autoimmune disorders in preclinical development. [10-K 2026-03-02]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$7.35M | −$6.73M | $4.96M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$28.35M | −$12.91M | $6.81M | [DEF 14A 2026-07-02] |
| FY ended Dec 2024 | — | −$13.16M | −$12.90M | $3.95M | [DEF 14A 2026-07-02] |
- Quarterly cash burn
- −$3.36M
- Cash runway Estimate
- ~4.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-10 | 2,234,328 | [10-Q 2024-11-14] |
| 2025-02-19 | 2,234,328 | [10-K/A 2025-04-14] |
| 2025-05-13 | 2,586,397 | [10-Q 2025-05-15] |
| 2025-08-08 | 3,557,502 | [10-Q/A 2026-03-06] |
| 2025-11-06 | 10,636,135 | [10-Q/A 2026-03-06] |
| 2026-02-23 | 31,553,892 | [10-K 2026-03-02] |
| 2026-05-08 | 36,062,904 | [10-Q 2026-05-15] |
| 2026-08-10 | 45,109,497 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2026-10-09; no effectiveness notice found in EDGAR [S-1 2026-10-09]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-05-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-05-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-22] |
| 2025-11-26 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-11-26] |
| 2024-11-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-27] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | S-1 | Registration statement |
| 2026-10-02 | PRE 14A | Proxy statement |
| 2026-09-25 | 8-K | Other events |
| 2026-09-21 | 8-K | Material agreement entered; Unregistered sale of equity; Change to security holder rights |
| 2026-09-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-15 | 8-K | Material agreement entered; Unregistered sale of equity; Change to security holder rights |
| 2026-09-03 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change; Other events |
| 2026-08-14 | 8-K | Shareholder vote results |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-07-02 | DEF 14A | Proxy statement |
| 2026-06-18 | PRE 14A | Proxy statement |
| 2026-06-12 | 8-K | Charter, bylaws or fiscal year change |
Alerts for $GTBP
Email me when GT Biopharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.